|
1
|
Souza LF, Souza VF, Silva LD, Santos JN
and Reis SR: Expression of basement membrane laminin in oral
squamous cell carcinomas. Braz J Otorhinolaryngol. 73:768–774.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sakamoto S and Kyprianou N: Targeting
anoikis resistance in prostate cancer metastasis. Mol Aspects Med.
31:205–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rajalalitha P and Vali S: Molecular
pathogenesis of oral submucous fibrosis-a collagenous metabolic
disorder. J Oral Pathol Med. 34:321–328. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reichart PA, van Wyk CW, Becker J and
Schuppan D: Distribution of procollagenous type III, collagenous
type VI and tenascin in oral submucous fibrosis (OSF). J Oral
Pathol Med. 23:394–398. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin HJ and Lin JC: Treatment of oral
submucous fibrosis by collagenousase: Effects on oral opening and
eating function. Oral Dis. 13:407–413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sumeth Perera MW, Gunasinghe D, Perera PA,
Ranasinghe A, Amaratunga P, Warnakulasuriya S and Kaluarachchi K:
Development of an in vivo mouse model to study oral submucous
fibrosis. J Oral Pathol Med. 36:273–280. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kerkelä E and Saarialho-Kere U: Matrix
metalloproteinases in tumor progression: Focus on basal and
squamous cell skin cancer. Exp Dermatol. 12:109–125. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stamenkovic I: Matrix metalloproteinases
in tumor invasion and metastasis. Semin Cancer Biol. 10:415–433.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sorsa T, Tjäderhane L and Salo T: Matrix
metalloproteinases (MMPs) in oral diseases. Oral Dis. 10:311–318.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seguier S, Gogly B, Bodineau A, Godeau G
and Brousse N: Is collagenous breakdown during periodontitis linked
to inflammatory cells and expression of matrix metalloproteinases
and tissue inhibitors of metalloproteinases in human gingival
tissue? J Periodontol. 72:1398–1406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stetler-Stevenson WG: Tissue inhibitors of
metalloproteinases in cell signaling: Metalloproteinase-independent
biological activities. Sci Signal. 1:re62008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boire A, Covic L, Agarwal A, Jacques S,
Sherifi S and Kuliopulos A: PAR1 is a matrix metalloprotease-1
receptor that promotes invasion and tumorigenesis of breast cancer
cells. Cell. 120:303–313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
George A, Ranganathan K and Rao UK:
Expression of MMP-1 in histopathological different grades of oral
squamous cell carcinoma and in normal buccal mucosa-an
immunohistochemical study. Cancer Biomark. 7:275–283.
2010.PubMed/NCBI
|
|
17
|
Zhou J, Brinckerhoff C, Lubert S, et al:
Analysis of matrix metalloproteinase-1 gene polymorphisms and
expression in benign and malignant breast tumors. Cancer Invest.
29:599–607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Durlik M and Gardian K: Metalloproteinase
2 and 9 activity in the development of pancreatic cancer. Pol
Przegl Chir. 84:377–382. 2012.PubMed/NCBI
|
|
19
|
Itoh T, Tanioka M, Yoshida H, Yoshioka T,
Nishimoto H and Itohara S: Reduced angiogenesis and tumor
progression in gelatinase A-deficient mice. Cancer Res.
58:1048–1051. 1998.PubMed/NCBI
|
|
20
|
Uhlmann ME, Georgieva M, Sill M, Linnemann
U and Berger MR: Prognostic value of tumor progression-related gene
expression in colorectal cancer patients. J Cancer Res Clin Oncol.
138:1631–1640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J and Cai Y: Matrix metalloproteinase
2 polymorphisms and expression in lung cancer: A meta-analysis.
Tumour Biol. 33:1819–1828. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang M, Teng XD, Guo XX, Li ZG, Han JG
and Yao L: Expression of tissue levels of matrix metalloproteinases
and their inhibitors in breast cancer. Breast. 22:330–334. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kurahara S, Shinohara M, Ikebe T, et al:
Expression of MMPS, MT-MMP and TIMPs in squamous cell carcinoma of
the oral cavity: Correlations with tumor invasion and metastasis.
Head Neck. 21:627–638. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakano K, Siar CH, Nagai N, et al:
Distribution of basement membrane type IV collagenous alpha chains
in ameloblastoma: An immunofluorescence study. J Oral Pathol Med.
31:494–499. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): Positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hojilla CV, Mohammed FF and Khokha R:
Matrix metalloproteinases and their tissue inhibitors direct cell
fate during cancer development. Br J Cancer. 89:1817–1821. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stetler-Stevenson WG: The tumor
microenvironment: Regulation by MMP-independent effects of tissue
inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 27:57–66.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagase H: Activation mechanisms of matrix
metalloproteinases. Biol Chem. 378:151–160. 1997.PubMed/NCBI
|
|
29
|
Stetler-Stevenson WG, Krutzsch HC and
Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new
member of the metalloproteinase inhibitor family. J Biol Chem.
264:17374–17378. 1989.PubMed/NCBI
|
|
30
|
Pradhan-Palikhe P, Vesterinen T, Tarkkanen
J, et al: Plasma level of tissue inhibitor of matrix
metalloproteinase-1 but not that of matrix metalloproteinase-8
predicts survival in head and neck squamous cell cancer. Oral
Oncol. 46:514–518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burduk PK, Bodnar M, Sawicki P, et al:
Expression of metalloproteinases 2 and 9 and tissue inhibitors 1
and 2 as predictors of lymph node metastases in oropharyngeal
squamous cell carcinoma. Head Neck. 37:418–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Giaginis C, Nikiteas N, Margeli A, et al:
Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and
TIMP-2) levels in colorectal cancer patients: Associations with
clinicopathological variables and patient survival. Int J Biol
Markers. 24:245–252. 2009.PubMed/NCBI
|
|
33
|
Chen D, Zheng J, Li H, Wang Q and Jiao X:
Computer-assisted morphometric analysis of lymphatic vessel changes
in hamster tongue carcinogenesis. J Oral Pathol Med. 39:518–524.
2010.PubMed/NCBI
|
|
34
|
Thompson L: World health organization
classification of tumours: Pathology and genetics of head and neck
tumours. Ear Nose Throat J. 85:742006.PubMed/NCBI
|
|
35
|
Chatterjee S, Mark ME, Wooley PH, et al:
Increased dermal elastic fibers in the tight skin mouse. Clin Exp
Rheumatol. 22:617–620. 2004.PubMed/NCBI
|
|
36
|
Ali FM, Patil A, Patil K and Prasant MC:
Oral submucous fibrosis and its dermatological relation. Indian
Dermatol Online J. 5:260–265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hong Q, Jun T, Lei J, Xiling J and
Tamamura R: Expression and clinical significance of matrix
metalloproteinase-2 and its inhibitor TIMP-2 in oral squamous cell
carcinoma. J Hard Tissue Biol. 2:54–60. 2006. View Article : Google Scholar
|
|
38
|
Santos-García A, Abad-Hernández MM,
Fonseca-Sánchez E, Julián-González R, Galindo-Villardón P,
Cruz-Hernández JJ and Bullón-Sopelana A: E-cadherin, laminin and
collagenous IV expression in the evolution from dysplasia to oral
squamous cell carcinoma. Med Oral Patol Oral Cir Bucal.
11:E100–E105. 2006.(In Spanish). PubMed/NCBI
|
|
39
|
Utsunomiya H, Tilakaratne WM, Oshiro K, et
al: Extracellular matrix remodeling in oral submucous fibrosis: Its
stage-specific modes revealed by immunohistochemistry and in situ
hybridization. J Oral Pathol Med. 34:498–507. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Krecicki T, Zalesska-Krecicka M, Jelen M,
et al: Expression of type IV collagenous and matrix
metalloproteinase-2 (type IV collagenousase) in relation to nodal
status in laryngeal cancer. Clin Otolaryngol Allied Sci.
26:469–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lazaris ACH, Tzoumani AN, Thimara I, et
al: Immunohistochemical assessment of basement membrane components
in colorectal cancer: prognostic implications. J Exp Clin Cancer
Res. 22:599–606. 2003.PubMed/NCBI
|
|
42
|
Shieh TY and Yang JF: Collagenousase
activity in oral submucous fibrosis. Proc Natl Sci Counc Repub
China B. 16:106–110. 1992.PubMed/NCBI
|
|
43
|
Yen CY, Chen CH, Chang CH, et al: Matrix
metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential
oral cancer markers. Biomarkers. 14:244–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
